MSLN and lung cancer: MSLN, a tumor differentiation antigen with the low expression on normal mesothelial cells, is overexpressed in a wide range of solid cancers, including lung cancer, mesothelioma, and pancreatic carcinoma; therefore, it could be used as a potential target (87, 88).